Circulating Tumor Cells (CTCs) in Advanced Gastric Cancer

NCT ID: NCT01848015

Last Updated: 2015-05-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-06-30

Study Completion Date

2016-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To assess the predictive value of circulating tumor cells (CTCs) for recurrence of advanced gastric cancer after radical resection.

To identify the relationship between the detection of circulation tumor cells and recurrence patterns of gastric cancer after radical resection.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gastric Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CTCs positive

detection of CTCs

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

detection of CTCs

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Having signed informed consent
* Age≄ 18 years old
* Histologically confirmed gastric adenocarcinoma
* Preoperative clinical examination and imaging indicating operable disease
* complete resection (R0 resection)
* D2 or D2+ resection

Exclusion Criteria

* Other tumor type than adenocarcinoma
* Patients who have been given preoperative chemotherapy/chemoradiation.
* Staging investigations or intraoperative exploration indicating inoperable disease
* R1 or R2 resection
* D0 or D1 resection
* Patients unreliable for follow up
* Past history of malignancy
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Peking University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Shen Lin

Director of GI oncology

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Lin Shen, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Peking University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Peking cancer hospital

Beijing, Beijing Municipality, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Lin Shen, MD,PhD

Role: CONTACT

(86)10-88196175

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Ming Lu, MD

Role: primary

(86)10-88196561

References

Explore related publications, articles, or registry entries linked to this study.

Zhang Q, Shan F, Li Z, Gao J, Li Y, Shen L, Ji J, Lu M. A prospective study on the changes and clinical significance of pre-operative and post-operative circulating tumor cells in resectable gastric cancer. J Transl Med. 2018 Jun 20;16(1):171. doi: 10.1186/s12967-018-1544-1.

Reference Type DERIVED
PMID: 29925382 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CGOG5003

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Rectal Cancer CTC Trial
NCT07194616 RECRUITING NA